CemiplimAb Survivorship Epidemiology
Part of paid clinical trials in Huntsville, Alabama.
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT03836105
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- cemiplimab — DRUGNo investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions.
Study Details
The objectives of the study are: * To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) cutaneous squamous cell carcinoma (CSCC) and patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) basal cell carcinoma (BCC) in real-world clinical settings * To evaluate the safety of cemiplimab based on incidence of treatment related immune-related adverse events (irAEs), infusion related reactions (IRRs), and treatment related serious adverse reactions (TSARs) in patients with advanced CSCC and patients with advanced BCC receiving cemiplimab treatment in real world clinical settings * To describe patient experience, including patient reported quality of life (QOL) and functional status, and clinician reported performance status in a real-world setting for patients with advanced CSCC and patients with advanced BCC * To describe baseline characteristics that could potentially be associated with health-related outcomes for patients with advanced CSCC and patients with advanced BCC undergoing treatment with cemiplimab * To describe patients who receive cemiplimab as treatment for CSCC or BCC in a real-world setting * To describe real-world use patterns of cemiplimab for CSCC and BCC * To investigate the long-term effects and effectiveness of cemiplimab in patients with advanced CSCC or advanced BCC * To describe the effectiveness of cemiplimab in immunosuppressed and immunocompetent patients with advanced CSCC or advanced BCC, regardless of etiology, per available data * To describe the effectiveness of cemiplimab after prior exposure to radiation therapy for CSCC per available data * To describe the effectiveness of cemiplimab as a first-line (1L) or later systemic treatment in patients with advanced CSCC, regardless of etiology, per available data * To describe the effectiveness of cemiplimab in patients with advanced BCC based on treatment patterns (reason for discontinuation, treatment exposure, etc) of prior Hedgehog inhibitor (HHI) usage
Key Dates
- Start date
- Jun 27, 2019
- Status verified
- Oct 2025
- Primary completion
- Sep 29, 2025
- Completion
- Sep 29, 2025
Study Design
- Enrollment
- 287 participants (actual)
Arms
- Arm: Group 1This group will enroll patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) CSCC.
- Arm: Group 2This group will enroll patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) BCC.
Primary Outcome Measure
Objective response rate (ORR) [ Time Frame: Up to 36 months ]
Locations (51)
Find similar trials in Huntsville, AL
Related Studies
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaPHASE2 · Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPHASE1 · Recruiting · Bicara Therapeutics · La Jolla, California
- Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaPHASE1 · Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsPHASE1 · Recruiting · Memgen, Inc. · Tampa, Florida